News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Johnson & Johnson Plant in Merck & Co., Inc. Venture Cited by U.S. FDA
July 20, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Johnson & Johnson (JNJ.N) has been cited by U.S. regulators for problems at a plant that is part of a consumer medicines joint venture with Merck & Co Inc (MRK.N), in a fresh blow to its manufacturing operations.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Johnson & Johnson Family of Companies
Merck & Co.
MORE ON THIS TOPIC
Kidney disease
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
September 23, 2026
·
2 min read
·
Annalee Armstrong
FDA
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
September 23, 2026
·
2 min read
·
Jef Akst
FDA
Compass vows to press on with FDA application despite new trial request
September 22, 2026
·
3 min read
·
Annalee Armstrong
FDA
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
September 16, 2026
·
1 min read
·
Jef Akst